U.S. Food and Drug Administration Issues Complete Response Letter for Empagliflozin

Boehringer Ingelheim Pharmaceuticals and Eli Lilly and Company announce the U.S. Food and Drug Administration have issued a complete response letter for the New Drug Application of the investigational sodium glucose co-transporter-2 (SGLT2) inhibitor empagliflozin (Lilly)